Diamantopoulos, Alex http://orcid.org/0000-0002-5700-6265
Maher, Toby M.
Schoof, Nils
Esser, Dirk
LeReun, Corinne
Funding for this research was provided by:
Boehringer Ingelheim
Article History
First Online: 25 June 2018
Compliance with Ethical Standards
: The INPULSIS-1 and INPULSIS-2 clinical trials were carried out in compliance with the clinical trial protocols, the principles laid down in the Declaration of Helsinki, in accordance with the International Conference on Harmonisation (ICH) Harmonised Tripartite Guideline for Good Clinical Practice (GCP) and in accordance with applicable regulatory requirements and Boehringer Ingelheim (BI) standard operating procedures.
: Informed consent was obtained from all individual participants included in the study.
: This study was funded by Boehringer Ingelheim International GmbH.
: Alex Diamantopoulos is employed by Symmetron Limited, which received funding from Boehringer Ingelheim International GmbH for this project. Alex Diamantopoulos has previously received funding from Boehringer Ingelheim for contributions to original research and similar articles. Toby M. Maher has received consulting fees from Symmetron Limited; industry-academic research funding from GlaxoSmithKline R&D and UCB; and consultancy or speaker’s fees from AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, Dosa, Galapagos, GlaxoSmithKline R&D, ProMetic, Roche (and previously InterMune), Sanofi-Aventis, Takeda and UCB. Toby M. Maher is supported by an NIHR Clinician Scientist Fellowship (NIHR ref: CS-2013-13-017) and British Lung Foundation Chair in Respiratory Research (C17-3). Nils Schoof and Dirk Esser are employees of Boehringer Ingelheim International GmbH. Corinne LeReun has received consulting fees from Symmetron Limited.